Biogen shares are down 36% from March, a decline that was primarily driven by weaker than expected (5% off forecasts) second quarter sales in addition to lowered sales guidance. We feel this stock could be oversold and could well post gains over the next year.
from Feed for all trade views http://ift.tt/1JP2CIW
#SaxoStrats: Biogen hitting bottom?
ad
Enregistrer un commentaire